Two 22q telomere deletions serendipitously detected by FISH

Kathrin S Precht, Christa M Lese, Rhonda P Spiro, Peter R Huttenlocher, Kathreen M Johnston, John C Baker, Susan L Christian, Kirk Kittikamron, David H Ledbetter

Abstract
Cryptic telomere deletions have been proposed to be a significant cause of idiopathic mental retardation. We present two unrelated subjects, with normal G banding analysis, in whom 22q telomere deletions were serendipitously detected at two different institutions using fluorescence in situ hybridisation (FISH). Both probands presented with several of the previously described features associated with 22q deletions, including hypotonia, developmental delay, and absence of speech. Our two cases increase the total number of reported 22q telomere deletions to 19, the majority of which were identified by cytogenetic banding analysis. With the limited sensitivity of routine cytogenetic studies (~2-5 Mb), these two new cases suggest that the actual prevalence of 22q telomere deletions may be higher than currently documented. Of additional interest is the phenotypic overlap with Angelman syndrome (AS) as it raises the possibility of a 22q deletion in patients whom AS has been ruled out. The use of telomeric probes as diagnostic reagents would be useful in determining an accurate prevalence of chromosome 22q deletions and could result in a significantly higher detection rate of subtelomeric rearrangements.

Subjects and methods
CASE REPORTS
Case 1, aged 5, is the second child of healthy, non-consanguineous parents. Her older brother is not reported to have any medical problems. The pregnancy was complicated by gestational diabetes, and she was delivered at term by caesarean section because of fetal distress, weighing 2580 g. She required nasogastric feeding for three days postnatally and was subsequently discharged at 5 days of age. Hypotonia and developmental delay were noted in infancy. She did not start walking until ~18 months and her gait remained unsteady with frequent falls. Her parents also noted a high pain tolerance. The family history included two maternal uncles with dyslexia and one with visual-spatial perception problems.

At 18 months, case 1 was assessed by a neurologist and investigations, including cranial MRI and C T scans as well as brainstem auditory evoked responses (BAERs), were normal. She never had seizures and an EEG at the age of 3 was normal. By the age of 4½, her persistent generalised developmental delay, particularly in the area of expressive speech, and her unsteady gait raised the possible diagnosis of Angelman syndrome. She was referred for cytogenetic and molecular genetic evaluation.

On examination at 4 years 10 months, her weight (17.8 kg), height (112 cm), and head...
circumference (50.5 cm) were all on the 50th centile. She had marked hypotonia, lax joints, and an uncoordinated gait. Her facial features were not dysmorphic. Her fingers were relatively wide with broad tips and she had bilateral fifth finger clinodactyly; there was mild 2-3 syndactyly of her toes. Physical examination was otherwise unremarkable. Psychological assessment at the time (Mullen Scales of Early Learning) placed her verbal and non-verbal skills at the 8 to 9 month and the 16 to 17 month level, respectively. The Bayley Scales of Infant Development indicated a mental age equivalent of 11-12 months.

Case 2, aged 3, is the second child of non-consanguineous parents. He was born at term, after an uncomplicated pregnancy, weighing 3742 g (90th centile). Although his neonatal period was unremarkable, developmental delay was noted in infancy. He sat unassisted at about 9-10 months and walked at 22 months. BAERs were borderline and a cranial MRI scan at the age of 2½ showed diminished periventricular white matter. Family history included a maternal great aunt with mental retardation and a maternal uncle with learning disabilities. By the age of 5, case 2 had no speech, but was able to use a few signs. On physical examination his height was 107 cm (25th centile), his weight was 40.5 kg (50th centile), and his head circumference was 52.5 cm (75th centile). His muscle tone was generally decreased and he made poor eye contact. He had bilateral epicanthic folds, narrow palpebral fissures, and a broad nasal root.

Previous investigations, which were all normal, included peripheral blood cytogenetic studies, molecular studies for fragile X, serum and urine amino acids, thyroid function tests, and an ophthalmological examination. He had narrow palpebral fissures, a broad nasal root, and his facial features were somewhat reminiscent of velocardiofacial syndrome. He was referred for further FISH evaluation to rule out a deletion at 22q11.2.

**CYTOGENETICS AND FISH**

Routine cytogenetic analysis at a greater than 550 band level was performed on peripheral blood samples from both probands and the parents of case 2 at either the University of Chicago Genetic Services (Chicago, IL) or Kaiser Permanente (Oakland, CA) using standard procedures.

Chromosome preparations from peripheral blood were used for fluorescence in situ hybridisation (FISH) analysis. FISH was initially performed on case 1 using D15S10, a probe for the Prader-Willi/Angelman region on chromosome 15 (Oncor Inc, Gaithersburg, MD). Samples from both patients were hybridised with a digoxigenin labelled commercial DiGeorge chromosome region probe, D22S375, containing the telomeric control locus D22S39, according to the manufacturer's conditions (Oncor Inc). The rapid wash procedure was followed with no amplification. The two probands were further studied with a chromosome 22q unique telomere probe, ICRF106G1220, labelled with digoxigenin-11-dUTP. A chromosome 14/22 alpha satellite probe, labelled with biotin-16-dUTP, was used to identify chromosome 22. Probe preparation, hybridisation, analysis, and imaging were carried out using previously described methods. Parental chromosome FISH studies were performed with the commercial DiGeorge probe and cosmids 106G1220 to rule out an inherited event.

**MICROSATELLITE ANALYSIS**

Microsatellite analysis was performed as previously described to confirm FISH results and determine the parental origin of deletion. Whole cell lysates were made from 200 μl of peripheral blood using the Qiamp blood lysis kit (Qiagen Inc, Chatsworth, CA). One μl of a 1:5 dilution of the cell lysate was used per PCR assay. Five Genethon STR markers from the distal portion of 22q were used: D22S283, S1179, S1140, S928, and S1169 (markers are listed in order from centromere to telomere).

**Results**

**CASE 1**

Cytogenetic and FISH analyses for Angelman syndrome were requested because of her early hypotonia and persistent lack of speech and...
unsteady gait. She was initially determined to have a normal female (46,XX) karyotype, and FISH showed no deletion for the Prader-Willi/ Angelman probe (D15S10) in proximal 15q.

Subsequently, her sample was used alongside that of another patient as a hybridisation control for the DGS/VCFS probe. Surprisingly, a deletion for the telomeric internal control locus (D22S39) was observed on one of her chromosome 22 homologues (fig 1A). This result was confirmed by a chromosome 22q unique telomere probe (c106G1220), classifying the deletion as terminal, rather than interstitial. Parental FISH studies were normal.

Of five microsatellite markers tested, four markers (D22S282, S1179, S1140, and S928) showed no evidence of a deletion. The most distal marker (D22S1169) was informative for the presence of a maternal band but absence of a paternal allele (fig 2), indicating a deletion of paternal origin.

CASE 2
Case 2 was referred for routine cytogenetic and FISH studies to rule out a VCFS deletion. Routine G banding analysis failed to identify any deletion of 22q. While the proximal 22q VCFS locus (D22S575) was present on both homologues, the distal control locus (D22S39) was found to be deleted on one homologue in all cells. Telomere FISH studies were performed using a unique sequence probe (c106G1220) which was also deleted, confirming the initial findings and ruling out an interstitial deletion (fig 1B). Parental chromosome and FISH studies were normal.

Three microsatellite markers (D22S282, S1140, S928) showed the presence of two alleles. The proband showed only one maternal and no paternal allele for the most distal marker (D22S1169), confirming a deletion and indicating a paternal origin (fig 2).

Discussion
Terminal 22q deletion patients share a common phenotype including hypotonia, developmental delay, and absence of speech. The additional clinical features, which vary among patients, may be the result of the different sizes and mechanisms of the deletions. Further molecular characterisation of all deletions, such as reported by Nesslinger et al,” would be useful for making genotype/phenotype correlations. In light of the initial findings from cytogenetic and microsatellite analyses of our patients, we would expect the deletions to be smaller than those previously reported. Further studies are under way to delineate the size of the deletions in these two cases. A smaller deletion may account for the milder phenotypes present in case 2, and particularly in case 1. A previously described patient with the smallest molecularly characterised 22q deletion of 130 kb showed only mild mental retardation, expressive speech delay, and no other abnormal physical findings. Since all of the patients with 22q terminal deletions are reported to have marked delay or absence of speech, this suggests that a gene(s) involved in expressive speech maps within 130 kb of the telomere.

While both of our probands share some of the clinical features of previously reported 22q telomere deletions, they were initially referred for cytogenetic studies for two different syndromes. Hypotonia and developmental delay are features commonly observed in many syndromes; however, in association with severe speech delay, these phenotypes may be a significant indication to test for a 22q deletion. The phenotypic similarity of these deletion patients to Angelman syndrome is particularly noteworthy, as it raises the possibility of a 22q deletion subset in patients with Angelman-like features in whom the syndrome has been ruled out. This hypothesis could be tested by combining 22q telomere FISH analysis with Angelman studies to determine if the overall deletion detection rate in such patients is increased.

The de novo deletion in both of our probands was determined to be of paternal origin. Two previously reported cases” were also paternal deletions. However, in four further cases, a maternal origin of the deletion was reported. Therefore, imprinting is an unlikely mechanism associated with the phenotype in these deletions.

The recently increasing number of reported 22q telomere deletions indicates that these types of deletion may be occurring more frequently than previously thought. The chance discovery of our two cases by FISH shows that detection of smaller deletions by routine cytogenetics is difficult because of its limited sensitivity and because the 22q telomeric region is G negative. Routine cytogenetic analysis or the use of whole chromosome painting probes would therefore be expected to miss smaller 22q telomere rearrangements. We conclude that FISH studies using telomeric probes for 22q are most suitable for ruling out and confirming deletions of this region.

We would like to acknowledge Dr Daniela Pilz for her assistance in manuscript preparation, Patti L Mills, MS and Christine Harlowe, MS for patient/sample coordination, and the University of Chicago Genetic Services laboratories for cell culture and sample preparation.


4 Zwaigenbaum L, Siegel-Bartelt J, Teshima I, Ho C. Two patients with 22q13 deletions have similar facies and developmental patterns. Am Hum Genet 1990;47:A45.


Two 22q telomere deletions serendipitously detected by FISH.


doi: 10.1136/jmg.35.11.939

Updated information and services can be found at:
http://jmg.bmj.com/content/35/11/939

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/